NEW YORK, NY--(Marketwire -03/05/12)- February was a challenging month for stem cell stocks. TickerSpy's Stem Cell Stocks Index (RXSTM) has slipped nearly 13 percent over the last month -- underperforming the S&P 500 by close to 17 percent over that time frame. Despite the drop in investor optimism, new research continues to propel the industry forward. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Advanced Cell Technology, Inc. (OTC.BB: ACTC.OB - News) and NeoStem, Inc. (AMEX: NBS - News). Access to the full company reports can be found at:

http://www.fivestarequities.com/ACTC

http://www.fivestarequities.com/NBS

A new study at Johns Hopkins University has shown that stem cells from patients' own cardiac tissue can be used to heal scarred tissue after a heart attack. "This has never been accomplished before, despite a decade of cell therapy trials for patients with heart attacks. Now we have done it," Eduardo Marban, director of the Cedars-Sinai Heart Institute and one of the study's co-authors, said in a statement. "The effects are substantial."

In another study, researchers led by Jonathan Tilly, director of the Vincent Center for Reproductive Biology at Massachusetts General Hospital, argue they've discovered the ovaries of young women harbor very rare stem cells capable of producing new eggs.

Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com and get exclusive access to our numerous stock reports and industry newsletters.

Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. The Company recently issued a press release stating that it utilized $13.6 million in cash for operations during 2011, compared to $8.8 million in the year-earlier period. The increase in cash utilization resulted primarily from ACT's ongoing clinical activities in the US and Europe.

NeoStem, Inc., a biopharmaceutical company, engages in the development and manufacture of cellular therapies for oncology, immunology, and regenerative medicines in the United States and China. In January, Amorcyte, LLC, a NeoStem, Inc. company, announced the enrollment of the first patient in the Amorcyte PreSERVE Phase 2 trial for acute myocardial infarction.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.fivestarequities.com/disclaimer

Excerpt from:
New Stem Cell Research Shows Promising Results -- Advanced Cell Tech and NeoStem Poised to Benefit